Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series

References

• Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nature Rev Dis Primers. 2017;3:17011. doi:10.1038/nrdp.2017.11
   PubMed Web of Science ®Google Scholar
• Ramírez-Marín HA, Tosti A. Emerging drugs for the treatment of alopecia areata. Expert Opinion on Emerging Drugs. 2022;27(4):379–387. doi:10.1080/14728214.2022.2149735
   PubMed Web of Science ®Google Scholar
• Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clin Rev Allergy Immunol. 2021;61(3):403–423. doi:10.1007/s12016-021-08883-0
   PubMed Web of Science ®Google Scholar
• Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E. Alopecia Areata: current Treatments and New Directions. Am j Clin Dermatol. 2023;24(6):895–912. doi:10.1007/s40257-023-00808-1
   PubMed Web of Science ®Google Scholar
• Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440–447. doi:10.1016/j.jaad.2003.09.032
   PubMed Web of Science ®Google Scholar
• Mikhaylov D, Pavel A, Yao C, et al. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatological Res. 2019;311(1):29–36. doi:10.1007/s00403-018-1876-y
   PubMed Web of Science ®Google Scholar
• Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol. 2006;20(10):1243–1247. doi:10.1111/j.1468-3083.2006.01781.x
   PubMed Web of Science ®Google Scholar
• Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1–12. doi:10.1016/j.jaad.2017.04.1141
   PubMed Web of Science ®Google Scholar
• Divito SJ, Kupper TS. Inhibiting Janus kinases to treat alopecia areata. Nature Med. 2014;20(9):989–990. doi:10.1038/nm.3685
   PubMed Web of Science ®Google Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nature Med. 2014;20(9):1043–1049. doi:10.1038/nm.3645
   PubMed Web of Science ®Google Scholar
• Upadacitinib. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
   Google Scholar
• Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776. doi:10.1172/jci.insight.89776
   PubMed Web of Science ®Google Scholar
• Jabbari A, Sansaricq F, Cerise J, et al. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis. J Investigative Dermatol. 2018;138(7):1539–1545. doi:10.1016/j.jid.2018.01.032
   PubMed Web of Science ®Google Scholar
• Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790. doi:10.1172/jci.insight.89790
   PubMed Web of Science ®Google Scholar
• Jabbari A, Dai Z, Xing L, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015;2(4):351–355. doi:10.1016/j.ebiom.2015.02.015
   PubMed Web of Science ®Google Scholar
• Kołcz K, Żychowska M, Sawińska E, Reich A. Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib-A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata. Dermatol therapy. 2023;13(3):843–856. doi:10.1007/s13555-023-00889-0
   PubMed Web of Science ®Google Scholar
• Johnston LA, Poelman SM. Upadacitinib for management of recalcitrant alopecia areata: a retrospective case series. JAAD case reports. 2023;35:38–42. doi:10.1016/j.jdcr.2023.02.019
   PubMedGoogle Scholar
• Flora A, Kozera E, Frew JW. Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: a retrospective cohort study. J Am Acad Dermatol. 2023;89(1):137–138. doi:10.1016/j.jaad.2022.12.056
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Balato A, Fabbrocini G, et al. Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study. J Am Acad Dermatol. 2023;89(6):1251–1253. doi:10.1016/j.jaad.2023.05.001
   PubMed Web of Science ®Google Scholar
• Asfour L, Getsos Colla T, Moussa A, Sinclair RD. Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib. Int J Dermatol. 2022;61(11):e416–e417. doi:10.1111/ijd.16316
   PubMed Web of Science ®Google Scholar
• Cantelli M, Martora F, Patruno C, Nappa P, Fabbrocini G, Napolitano M. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatologic Therapy. 2022;35(4):e15346. doi:10.1111/dth.15346
   PubMed Web of Science ®Google Scholar
• Uchida H, Kamata M, Watanabe A, et al. Improvement of severe alopecia areata after 9-month baricitinib treatment followed by subsequent use of upadacitinib in a patient with atopic dermatitis. J Dermatol. 2023;50(11):e392–e393. doi:10.1111/1346-8138.16893
   PubMed Web of Science ®Google Scholar
• Walls B, Reguiai Z. Dual efficacy of upadacitinib in a patient with concomitant severe atopic dermatitis and alopecia areata. Ann de dermatologie et de venereologie. 2023;150(4):281–283. doi:10.1016/j.annder.2023.03.010
   PubMed Web of Science ®Google Scholar
• Gambardella A, Licata G, Calabrese G, De Rosa A, Alfano R, Argenziano G. Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata. Dermatitis. 2021;32(1s):e85–e86. doi:10.1097/der.0000000000000780
   PubMed Web of Science ®Google Scholar